Bonell Patiño-Escobar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bonell Patiño-Escobar has a total of 297 co-authors. Here are the top co-authors by number of shared publications:
- Arun P. Wiita
Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA
144 shared publications - Veronica Steri
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
137 shared publications - Anil Parsram Bidkar
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
136 shared publications - Anju Wadhwa
University of California, San Francisco 1 Department of Radiology and Biomedical Imaging San Francisco, California
136 shared publications - Bin Liu
Department of Anesthesia, University of California, San Francisco, San Francisco, California
136 shared publications - David Meybin Wilson
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
136 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S33 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S33. Body weight measurements for the MM.1S disseminated tumor-bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S33 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S33. Body weight measurements for the MM.1S disseminated tumor-bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S34 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S34. Body weight measurements for the RPMI disseminated tumor bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S34 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S34. Body weight measurements for the RPMI disseminated tumor bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S29 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S29. PET/CT imaging of relapsed tumors using [89Zr]DFO-YS5, showing axial, coronal, and maximum intensity projection (MIP) views. The imaging demonstrates uptake of [89Zr]DFO-YS5 in tumors, confirming the presence of CD46 expression on relapsed tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S29 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S29. PET/CT imaging of relapsed tumors using [89Zr]DFO-YS5, showing axial, coronal, and maximum intensity projection (MIP) views. The imaging demonstrates uptake of [89Zr]DFO-YS5 in tumors, confirming the presence of CD46 expression on relapsed tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S21 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S21. PET imaging and biodistribution of [134Ce]Macropa-PEG4-YS5 in 22Rv1 tumor-bearing mice. Axial, coronal PET/CT, and MIP images of 22Rv1 tumor-bearing mice were acquired at 24, 48, 96, and 168 hours following intravenous administration of [134Ce]Macropa-PEG4-YS5, illustrating tracer biodistribution and tumor uptake over time.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S21 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S21. PET imaging and biodistribution of [134Ce]Macropa-PEG4-YS5 in 22Rv1 tumor-bearing mice. Axial, coronal PET/CT, and MIP images of 22Rv1 tumor-bearing mice were acquired at 24, 48, 96, and 168 hours following intravenous administration of [134Ce]Macropa-PEG4-YS5, illustrating tracer biodistribution and tumor uptake over time.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S24 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S24. µPET/CT imaging and biodistribution with [89Zr]DFO*-YS5-MMAE in 22Rv1 tumor-bearing mice. (A). Axial, coronal, and maximum intensity projection (MIP) PET/CT images of mice (M1–M4) at 24, 48, 96, and 168 hours post-injection of [89Zr]DFO*-YS5-MMAE. The images show sustained and specific uptake in 22Rv1 tumors over time. Color scale represents % injected dose per gram of tissue (%ID/g), indicating consistent tumor retention up to 7 days post-injection. (B) Biodistribution of [89Zr]DFO-YS5-MMAE in 22Rv1 tumor-bearing mice at 168 hours post-injection (n=4).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S24 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S24. µPET/CT imaging and biodistribution with [89Zr]DFO*-YS5-MMAE in 22Rv1 tumor-bearing mice. (A). Axial, coronal, and maximum intensity projection (MIP) PET/CT images of mice (M1–M4) at 24, 48, 96, and 168 hours post-injection of [89Zr]DFO*-YS5-MMAE. The images show sustained and specific uptake in 22Rv1 tumors over time. Color scale represents % injected dose per gram of tissue (%ID/g), indicating consistent tumor retention up to 7 days post-injection. (B) Biodistribution of [89Zr]DFO-YS5-MMAE in 22Rv1 tumor-bearing mice at 168 hours post-injection (n=4).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S23 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S23. Magnetic beads assay showing binding of [89Zr]DFO*-YS5-MMAE confirming retention of immunoreactivity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S23 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S23. Magnetic beads assay showing binding of [89Zr]DFO*-YS5-MMAE confirming retention of immunoreactivity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S22 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S22. Biodistribution of [134Ce]Macropa-PEG4-YS5 and [134Ce]Macropa-PEG4-YS5-MMAE in 22Rv1 tumor-bearing mice at 168 hours post-injection (n=4). %IA/g values are shown for major organs, including the liver, kidneys, spleen, and tumor.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S22 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S22. Biodistribution of [134Ce]Macropa-PEG4-YS5 and [134Ce]Macropa-PEG4-YS5-MMAE in 22Rv1 tumor-bearing mice at 168 hours post-injection (n=4). %IA/g values are shown for major organs, including the liver, kidneys, spleen, and tumor.